LRMR
Larimar Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$523.57M
P/E Ratio
—
EPS
$-2.27
Beta
1.02
52W High
$6.42
52W Low
$1.72
50-Day MA
$4.23
200-Day MA
$3.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-172.15M |
| Operating Margin | 0.00% |
| Return on Equity | -132.60% |
| Return on Assets | -62.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.94 |
| Price-to-Book | 6.35 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $103.88M |
| Float | $54.99M |
| % Insiders | 0.88% |
| % Institutions | 75.20% |
Analyst Ratings
Consensus ($16.70 target)
1
Strong Buy10
BuyData last updated: 4/8/2026